Abstract Number: 2426 • 2017 ACR/ARHP Annual Meeting
Altered Frequencies of Circulating Follicullar T Helper Cell Counterparts and Their Subsets but Not of Peripheral Helper T Cells, Are Associated with Increased Circulating Plasmablasts in Seropositive Early RA Patients
Background/Purpose: Follicular T helper (Tfh) cells are typically located in lymphoid organs where they promote B cell differentiation and function. Circulating CD4 T cells expressing…Abstract Number: 2427 • 2017 ACR/ARHP Annual Meeting
Exosomes Derived from T Lymphocytes Enhance Expression of CXCL10 Induced By IFN-γin Rheumatoid Arthritis Synovial Fibroblasts Via Pattern Recognition Receptor, RIG-I
Background/Purpose: Exosomes have been recognized to have a function in cell-to-cell communication by transporting various factors including proteins and nucleic acids. These factors impact cell…Abstract Number: 2428 • 2017 ACR/ARHP Annual Meeting
Epstein-Barr Virus Infection and Epstein-Barr Virus Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis
Background/Purpose: Epstein-Barr virus (EBV) infection causes various malignant tumors such as B cell lymphoma and epithelial cell cancer. Previous reports showed several variants in carboxyl-terminal…Abstract Number: 2429 • 2017 ACR/ARHP Annual Meeting
Towards Precision Medicine in Rheumatoid Arthritis (RA): Trans-Ethnic Analysis and Prioritization of SNPs in the AFF3 Locus
Background/Purpose: Genetic variants in AFF3 have been associated with RA, including in our GWAS and ImmunoChip analyses of African-Americans (610 RA; 1543 controls). Likewise, an…Abstract Number: 2430 • 2017 ACR/ARHP Annual Meeting
For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4
HLA-DRB1 genotypic risk to develop ACPA positive RA correlates with capability of encoded HLA-DRB1 chains to bind Peptidyl Arginyl Deiminase (PAD4) peptides, not citrullinated Fibrinogen…Abstract Number: 2431 • 2017 ACR/ARHP Annual Meeting
Acquisition of Protective Alleles in Women with Rheumatoid Arthritis through Microchimerism
Background/Purpose: As in many autoimmune diseases, rheumatoid arthritis (RA) has a female predominance and strong genetic susceptibility from the HLA region. The shared epitope (SE),…Abstract Number: 2432 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Gene Expression Associated with Disease Activity during Pregnancy and Post-Partum Among Women with Rheumatoid Arthritis
Background/Purpose: Many women with rheumatoid arthritis (RA) experience an improvement in disease activity during pregnancy, and a predictable flare in the months after they give…Abstract Number: 2433 • 2017 ACR/ARHP Annual Meeting
Transcriptome Analysis in Women with Rheumatoid Arthritis Who Improve or Worsen during Pregnancy
Background/Purpose: Gene expression changes induced by pregnancy in women with rheumatoid arthritis (RA) and healthy women have not been examined. The few studies previously conducted…Abstract Number: 2434 • 2017 ACR/ARHP Annual Meeting
Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy
Background/Purpose: MicroRNAs (miRNAs) post-transcriptionally regulate gene expression by targeting messenger RNAs. The expression of miRNAs was demonstrated to differ between patients with rheumatoid arthritis (RA)…Abstract Number: 2435 • 2017 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Biomarkers of Cardiovascular Disease in Rheumatoid Arthritis Patients
Background/Purpose: Extracellular microRNAs, circulating in the bloodstream and extracellular space, have been proposed as attractive candidates as both diagnostic and prognostic biomarkers in various diseases,…Abstract Number: 2436 • 2017 ACR/ARHP Annual Meeting
MiR-146a Upregulates the TLR4/NF-κb Signaling Pathway to Promote Cytokine Expression and Synovial Fibroblast Proliferation in Rheumatoid Arthritis
Background/Purpose: To investigate the role of miR-146a in the activation of toll-like receptor-4 (TLR4)/ nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, and…Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…Abstract Number: 2439 • 2017 ACR/ARHP Annual Meeting
Switching from RA Originator to Biosimilar in Routine Clinical Care: Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: Biosimilars, biopharmaceuticals assessed by regulatory agencies to have efficacy and safety similar to their reference products, were introduced to the UK market in February…Abstract Number: 2440 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy, Safety and Immunogenicity Results from a Randomized, Double-Blind, Phase III Confirmatory Efficacy and Safety Study Comparing GP2017, a Proposed Biosimilar, with Reference Adalimumab
Background/Purpose: Based on the evaluation of physicochemical, biological, preclinical, and clinical data, a biosimilar may be approved for use in the same indications for which…
ACR Meeting Abstracts